Drug-delivering nanoparticles designed to glow when their target cells die can report on the effectiveness of cancer therapies within just a few hours of treatment, a mouse study shows.
While exploring the genetics of a rare type of tumor, Stephen Baylin discovered an epigenetic modification that occurs in most every cancer—a finding he’s helping bring to the clinic.